|
1) Scott WJ, Schwabe JL, Gupta NC, et al. Positron emission tomography of lung tumors and mediastinal lymph nodes using [18F] fluorodeoxyglucose. Ann Thorac Surg. 1994; 58: 698-703
|
|
|
|
2) Patz EF, Lowe VJ, Hoffman JM, et al. Focal pulmonary abnormalities: Evaluation with F-18 fluorodeoxyglucose PET scanning. Radiology. 1993; 188: 487-90
|
|
|
|
|
|
3) Gupta NC, Maloof J, Gunel E. Probability of malignancy in solitary pulmonary nodules using fluorine-18-FDG and PET. J Nucl Med. 1996; 37: 943-8
|
|
|
|
|
|
4) Gupta NC, Gill H, Graeber G, et al. Dynamic positron emission tomography with F-18 fluoro-deoxyglucose imaging in differentiation of benign from malignant lung/mediastinal lesions. Chest. 1998; 114: 1105-11
|
|
|
|
|
|
5) Higashi K, Ueda Y, Seki H, et al. Fluorine-18-FDG PET imaging is negative in bronchiolo-alveolar carcinoma. J Nucl Med. 1998; 39: 1016-20
|
|
|
|
|
|
6) Imdahl A, Jenkner S, Brink I, et al. Validation of FDG positron emission tomography for differentiation of unknown pulmonary lesions. Eur J Cardiothorac Surg. 2001; 20: 324-9
|
|
|
|
|
7) Coleman RE. PET in lung cancer. J Nucl Med. 1999; 40: 814-20
|
|
|
|
|
|
8) McLoud TC. Imaging techniques for diagnosis and staging of lung cancer. Clinics in Chest Med. 2002; 23: 123-36
|
|
|
|
|
|
9) Lowe VJ, Fletcher JW, Gobar L, et al. Prospective investigation of positron emission tomography in lung nodules. J Clin Oncol. 1998; 16: 1075-84
|
|
|
|
|
|
10) Gould MK, Maclean CC, Kuschner WG, et al. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA. 2001; 285: 914-24
|
|
|
|
|
|
11) Nomori H, Watanabe K, Ohtsuka T, et al. Evaluation of F-18 fluorodeoxyglucose (FDG) PET scanning for pulmonary nodules less than 3cm in diameter, with special reference to the CT images. Lung Cancer. 2004; 45: 19-27
|
|
|
|
|
|
12) Dwamena BA, Sonnad SS, Angobaldo JO, et al. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s─Meta-analytic comparison of PET and CT. Radiology. 1999; 213: 530-6
|
|
|
|
|
|
13) Nomori H, Watanabe K, Ohtsuka T, et al. The size of metastatic foci and lymph nodes yielding false-negative and false-positive lymph node staging with positron emission tomography in patients with lung cancer. J Thorac Cardiovasc Surg. 2004; 127: 1087-92
|
|
|
|
|
|
14) Ebihara A, Nomori H, Watanabe K, et al. Characteristics of advantages of positron emis-sion tomography over computed tomography for N-staging in lung cancer patients. Jpn J Clin Oncol. 2006; 36: 694-8
|
|
|
|
|
15) Nomori H, Watanabe K, Ohtsuka T, et al. Fluorine 18-tagged fluorodeoxyglucose positron emission tomographic scanning to predict lymph node metastasis, invasiveness, or both, in clinical T1N0M0 lung adenocarcinoma. J Thorac Cardiovasc Surg. 2004; 128: 396-401
|
|
|
|
|
|
16) Watanabe K, Nomori H, Ohtsuka T, et al. F-18 fluorodeoxyglucose positron emission tomo-graphy can predict pathological tumor stage and proliferative activity determined by Ki-67 in clinical stage IA lung adenocarcinoma. Jap J Clin Oncol. 2006; 36: 403-9
|
|
|
|
|
|
17) 渡辺健一, 野守裕明, 大塚 崇, 他. 3cm以下末梢小型肺癌に対するF-18 fluorodeoxyglucose-positron emission tomography (FDG-PET)偽陰性症例の臨床病理学的検討. 日本呼吸器学会雑誌. 2004; 42: 787-93
|
|
|
|
|
|
18) Cerfolio RJ, Bryant AS, Ohja B, et al. The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival. J Thorac Cardiovasc Surg. 2005; 130: 151-9
|
|
|
|
|
|
19) Ohtsuka T, Nomori H, Watanabe K, et al. Prognostic significance of [18F] fluorodeoxyglucose uptake on positron emission tomography in patients with pathological stage I lung adenocarcinoma. Cancer. 2006; 107: 2468-73
|
|
|
|
|